The Experts below are selected from a list of 657180 Experts worldwide ranked by ideXlab platform
Xianglin Cheng - One of the best experts on this subject based on the ideXlab platform.
-
association between Rs1801133 polymorphism and risk of adult ischemic stroke meta analysis based on case control studies
Thrombosis Research, 2016Co-Authors: Min Chen, Ben Yu Mao, Dan Wang, Xianglin ChengAbstract:Abstract Background This study is aimed to quantify the strength of the association between Rs1801133 polymorphism and ischemic stroke risk. Methods We have searched Medline, Springer, and Embase for studies investigating the association between Rs1801133 polymorphism and ischemic stroke risk. We estimated the pooled odds ratio with its 95% confidence intervals to assess this possible association. Results Forty case–control studies comprising 8809 cases and 9130 controls are eligible for this meta-analysis on the basis of relation of Rs1801133 polymorphism to ischemic stroke risk. Hardy-Weinberg equilibrium was used to perform in controls for excluding articles. The overall analysis suggested that Rs1801133 polymorphism was associated with increased risk of ischemic stroke (OR T versus C =1.16, 95% CI 1.10–1.22; OR TT versus TC+CC =1.32, 95% CI 1.18–1.47; OR TT+TC versus CC =1.11, 95% CI 1.04–1.18). Subgroup analysis showed that T allele was a significant strength between T allele and stroke risk in Asian, Caucasian, male and young-middle populations (OR=1.19, 1.11, 1.30, 1.16, respectively). Compared with TC+CC, TT genotype was found to be a risk factor for developing ischemic stroke in Asian, Caucasian and male (OR=1.41, 1.20, 1.77, respectively). Additionally, TT+TC retained a significant increase for ischemic stroke only in Asian comparable to CC genotype (OR=1.14). Conclusions The Rs1801133 polymorphism could be capable of increasing ischemic stroke susceptibility in Asian, male and young-middle populations.
-
Association between Rs1801133 polymorphism and risk of adult ischemic stroke: Meta-analysis based on case–control studies
Thrombosis research, 2015Co-Authors: Min Chen, Ben Yu Mao, Dan Wang, Xianglin ChengAbstract:Abstract Background This study is aimed to quantify the strength of the association between Rs1801133 polymorphism and ischemic stroke risk. Methods We have searched Medline, Springer, and Embase for studies investigating the association between Rs1801133 polymorphism and ischemic stroke risk. We estimated the pooled odds ratio with its 95% confidence intervals to assess this possible association. Results Forty case–control studies comprising 8809 cases and 9130 controls are eligible for this meta-analysis on the basis of relation of Rs1801133 polymorphism to ischemic stroke risk. Hardy-Weinberg equilibrium was used to perform in controls for excluding articles. The overall analysis suggested that Rs1801133 polymorphism was associated with increased risk of ischemic stroke (OR T versus C =1.16, 95% CI 1.10–1.22; OR TT versus TC+CC =1.32, 95% CI 1.18–1.47; OR TT+TC versus CC =1.11, 95% CI 1.04–1.18). Subgroup analysis showed that T allele was a significant strength between T allele and stroke risk in Asian, Caucasian, male and young-middle populations (OR=1.19, 1.11, 1.30, 1.16, respectively). Compared with TC+CC, TT genotype was found to be a risk factor for developing ischemic stroke in Asian, Caucasian and male (OR=1.41, 1.20, 1.77, respectively). Additionally, TT+TC retained a significant increase for ischemic stroke only in Asian comparable to CC genotype (OR=1.14). Conclusions The Rs1801133 polymorphism could be capable of increasing ischemic stroke susceptibility in Asian, male and young-middle populations.
Monir Sadat Haerian - One of the best experts on this subject based on the ideXlab platform.
-
MTRR rs1801394 and its interaction with MTHFR Rs1801133 in colorectal cancer: a case-control study and meta-analysis.
Pharmacogenomics, 2017Co-Authors: Monir Sadat Haerian, Batoul Sadat Haerian, Saadat Molanaei, Farid Kosari, Shahram Sabeti, Farahnaz Bidari-zerehpoosh, Ebrahim AbdolaliAbstract:Aim: This study aims to evaluate the association between the MTRR rs1801394 alone or in interaction with the MTHFR Rs1801133 and susceptibility to colorectal cancer (CRC) and its characteristics in Iranian population. Additionally, both a systematic review and meta-analysis were performed to derive a more precise assessment of this association. Materials & methods: Genomic DNA of 2332 subjects was genotyped for rs1801394. These data were pooled with 17 eligible studies for meta-analysis. Results: No significant association was found between the rs1801394 or rs1801394-Rs1801133 and CRC risk. Meta-analysis results also demonstrated no significant relationship between the rs1801394 and CRC risk. Conclusion: Results of this study showed that the rs1801394 alone or together with the Rs1801133 is not a risk factor for CRC in Iranian population.
-
mthfr Rs1801133 polymorphism and susceptibility to colorectal cancer in iranian population evidence of a case control study and meta analysis
Pharmacogenomics, 2016Co-Authors: Monir Sadat Haerian, Batoul Sadat Haerian, Saadat Molanaei, Farid Kosari, Shahram Sabeti, Ebrahim Abdolali, Farahnaz Bidarizerehpoosh, Mohammad Reza ZaliAbstract:Several studies have investigated whether MTHFR Rs1801133 polymorphism contributes to risk of colorectal cancer (CRC), however the results are inconclusive. Aim: The purpose of this study was to investigate this hypothesis in a case–control study and meta-analysis in Iranian population. Materials & methods: This polymorphism was genotyped in the 2421 subjects (46% CRC patients) from Tehran. Meta-analysis was performed for determining the risk effect size of this polymorphism on CRC. Results: Both case–control study and meta-analysis showed no association between Rs1801133 and CRC risk or its features. Conclusion: This study failed to identify an association between the Rs1801133 and susceptibility to CRC in Iranian population.
-
MTHFR Rs1801133 polymorphism and susceptibility to colorectal cancer in Iranian population: evidence of a case–control study and meta-analysis
Pharmacogenomics, 2016Co-Authors: Monir Sadat Haerian, Batoul Sadat Haerian, Saadat Molanaei, Farid Kosari, Shahram Sabeti, Farahnaz Bidari-zerehpoosh, Ebrahim Abdolali, Mohammad Reza ZaliAbstract:Several studies have investigated whether MTHFR Rs1801133 polymorphism contributes to risk of colorectal cancer (CRC), however the results are inconclusive. Aim: The purpose of this study was to investigate this hypothesis in a case–control study and meta-analysis in Iranian population. Materials & methods: This polymorphism was genotyped in the 2421 subjects (46% CRC patients) from Tehran. Meta-analysis was performed for determining the risk effect size of this polymorphism on CRC. Results: Both case–control study and meta-analysis showed no association between Rs1801133 and CRC risk or its features. Conclusion: This study failed to identify an association between the Rs1801133 and susceptibility to CRC in Iranian population.
-
Evaluation of association studies and meta-analyses of MTHFR gene polymorphisms in colorectal cancer
Pharmacogenomics, 2015Co-Authors: Batoul Sadat Haerian, Monir Sadat HaerianAbstract:There is a discrepancy between the results of 89 original studies and 15 meta-analyses investigating the association of MTHFR Rs1801133 and rs1801131 polymorphisms with colorectal cancer (CRC) risk. We examined this hypothesis through meta-analyses of both loci and their diplotypes as well as evaluation of previous meta-analyses. The present meta-analysis showed that Rs1801133 and rs1801131 might be CRC susceptibility variants in Americans and Australians and Rs1801133 in Brazilians and Japanese. A strong linkage disequilibrium was observed between both loci and their diplotypes were associated with CRC risk. Evaluation of 15 meta-analyses showed a high discrepancy among their findings, mainly caused by population stratification of original studies and data analysis strategies in meta-analysis. Population stratification was more dominant in the studies from Australia, America and Brazil leading to false positive or negative results. In conclusion, these loci alone might modify the development of CRC in some ethnicities.
Hao Deng - One of the best experts on this subject based on the ideXlab platform.
-
association of the mthfr rs1801131 and Rs1801133 variants in sporadic parkinson s disease patients
Neuroscience Letters, 2016Co-Authors: Lamei Yuan, Zhi Song, Xiong Deng, Wei Xiong, Zhijian Yang, Hao DengAbstract:Parkinson's disease (PD) is a common age-dependent neurodegenerative movement disorder related to multiple factors, and genetic factors play an important role in the pathogenesis of PD. Variants in the methylenetetrahydrofolate reductase gene (MTHFR), a gene encoding a folate-dependent enzyme that is involved in homocysteine metabolism, have been reported to be associated with PD. To explore the role of the MTHFR gene in the development of PD in Chinese Han population, we analyzed two MTHFR variants (rs1801131 and Rs1801133) in a patient cohort consisting of 512 patients with PD from mainland China and a control cohort consisting of 512 age, gender and ethnicity matched normal subjects. Statistically significant differences in genotypic and allelic frequencies were detected in the MTHFR variant Rs1801133 (P=0.022 and 0.007, respectively; odds ratio=0.780, 95% confidence interval=0.651-0.934). In addition, the A-T haplotype of rs1801131-Rs1801133 showed a protective role against PD development (P=0.007, odds ratio=0.779, 95% confidence interval=0.650-0.933). Our results suggested that the T allele of Rs1801133 variant and A-T haplotype of rs1801131-Rs1801133 in the MTHFR gene may decrease the risk of developing PD in Chinese Han population from mainland China.
-
Association of the MTHFR rs1801131 and Rs1801133 variants in sporadic Parkinson’s disease patients
Neuroscience letters, 2016Co-Authors: Lamei Yuan, Zhi Song, Xiong Deng, Wei Xiong, Zhijian Yang, Hao DengAbstract:Parkinson's disease (PD) is a common age-dependent neurodegenerative movement disorder related to multiple factors, and genetic factors play an important role in the pathogenesis of PD. Variants in the methylenetetrahydrofolate reductase gene (MTHFR), a gene encoding a folate-dependent enzyme that is involved in homocysteine metabolism, have been reported to be associated with PD. To explore the role of the MTHFR gene in the development of PD in Chinese Han population, we analyzed two MTHFR variants (rs1801131 and Rs1801133) in a patient cohort consisting of 512 patients with PD from mainland China and a control cohort consisting of 512 age, gender and ethnicity matched normal subjects. Statistically significant differences in genotypic and allelic frequencies were detected in the MTHFR variant Rs1801133 (P=0.022 and 0.007, respectively; odds ratio=0.780, 95% confidence interval=0.651-0.934). In addition, the A-T haplotype of rs1801131-Rs1801133 showed a protective role against PD development (P=0.007, odds ratio=0.779, 95% confidence interval=0.650-0.933). Our results suggested that the T allele of Rs1801133 variant and A-T haplotype of rs1801131-Rs1801133 in the MTHFR gene may decrease the risk of developing PD in Chinese Han population from mainland China.
Baohui Han - One of the best experts on this subject based on the ideXlab platform.
-
heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non small cell lung cancer nsclc patients treated with platinum based chemotherapy
Tumor Biology, 2014Co-Authors: Minhua Shao, Shiming Wang, Xueying Zhao, Hongyan Chen, Ji Qian, Xiao Song, Jiucun Wang, Li Jin, Chunxue Bai, Baohui HanAbstract:Methylenetetrahydrofolate reductase (MTHFR) enzyme is essential for transmethylation reactions including DNA methylation and DNA synthesis and thereby may contribute to cancer prognosis. In our study, a total of 1,004 advanced non-small cell lung cancer (NSCLC) patients receiving first-line, platinum-based chemotherapy regimens were used for genotyping 10 tag single nucleotide polymorphisms (SNPs) of MTHFR. Association was assessed between the SNPs and treatment outcomes. We found that polymorphism of rs1537514 showed the most significant effect: heterozygote associated with better clinical benefit (P = 0.002) and decreased risk of grade 3 or 4 gastrointestinal toxicity (P = 0.027), while the mutant homozygote associated with increased risk of severe gastrointestinal toxicity (P = 0.031) and thrombocytopenia (P = 0.009). The heterozygotes of exon polymorphisms (rs1801131, Rs1801133) also yielded better clinical benefit (P = 0.030 for rs1801131) and decreased risk of severe gastrointestinal toxicity (P = 0.004 for rs1801131) or thrombocytopenia (P = 0.016 for 1801133). However, overall survival (OS) and progression-free survival (PFS) did not differ for the MTHFR polymorphisms, except for heterozygote of rs1537514 showing significant effects with better PFS (P = 0.022). Clinical factors as age, gender, and smoking status had significant effects for the OS (P = 0.003, 0.002, and 0.012, respectively) while performance status and chemotherapy regimens for PFS (P = 0.001 and 3.9 × 10−6, respectively). The results indicate that a heterozygous advantage may exist in certain MTHFR variants, and the polymorphisms (especially rs1537514) may play a predictive role of treatment efficacy and adverse effects in NSCLC patients treated with platinum-based chemotherapy.
Na-na Yang - One of the best experts on this subject based on the ideXlab platform.
-
Methylenetetrahydrofolate reductase gene polymorphism and risk of type 2 diabetes mellitus.
PloS one, 2013Co-Authors: Jian-hong Zhong, A. Chapin Rodríguez, Na-na YangAbstract:Objective This review aimed to comprehensively assess the literature examining a possible link between the Rs1801133 polymorphism (677C→T) in the gene encoding the methylenetetrahydrofolate reductase (MTHFR) gene and risk of type 2 diabetes mellitus (DM). Research Design and Methods Several research databases were systematically searched for studies examining the genotype at the Rs1801133 polymorphism in healthy control individuals and individuals with type 2 DM. Genotype frequency data were examined across all studies and across subsets of studies according to ethnicity and presence of serious DM-related complications. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Results A total of 4855 individuals with type 2 DM and 5242 healthy controls from 15 countries comprising Asian, Caucasian and African ethnicities were found to satisfy the inclusion criteria and included in the review. Genotype at the Rs1801133 polymorphism was not consistently associated with either increased or reduced risk of type 2 DM; the OR across all studies was 0.91 (95%CI 0.82 to 1.00) for the C- vs. T-allele, 0.88 (0.75 to 1.03) for CC vs. CT+TT, 0.82 (0.71 to 0.95) for CC vs. TT, and 1.15 (1.03 to 1.29) for TT vs. CC+CT. Similar results were found when the meta-analysis was repeated separately for each ethnic subgroup, and for subgroups with or without serious DM-related complications. Conclusions There does not appear to be compelling evidence of an association between the genotype at the Rs1801133 polymorphism of the MTHFR gene and risk of type 2 DM.
